Serial IGRA screening for lung cancer patients receiving immune checkpoint inhibitors

Serial IGRA screening for lung cancer patients receiving immune checkpoint inhibitors - IGRA screening for lung cancer patients receiving immune checkpoint inhibitors

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036533

Enrollment

200

Registered

2019-04-22

Start date

2019-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer patients who receiving immune checkpoint inhibitors

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Lung cancer patients who receiving immune checkpoint inhibitors

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
positive conversion rate of IGRA at a year after induction of immune checkpoint inhibitor therapy	—

Secondary

Measure	Time frame
incidence of active TB at a year after induction of immune checkpoint inhibitor therapy	—

Countries

Japan

Contacts

Public ContactKohei Fujita

National Hospital Organization Kyoto Medical Center Respiratory Medicine

kfujita-oka@umin.ac.jp0756419161

Outcome results